




- (51) International Patent Classification:
A61M 1/00 (2006.01)
- (21) International Application Number:
PCT/US2015/057240
- (22) International Filing Date:
23 October 2015 (23.10.2015)
- (25) Filing Language:
English
- (26) Publication Language:
English
- (30) Priority Data:
62/068,425 24 October 2014 (24.10.2014) US
- (71) Applicant: **KCI LICENSING, INC.** [US/US]; Legal Department-intellectual Property, P.O. Box 659508, San Antonio, TX 78265-9508 (US).

- (72) Inventors: **PRATT, Benjamin, Andrew**; 1 Winifred Road, Poole, Dorset BH15 3PU (GB). **LOCKE, Christopher, Brian (Chris)**; 6 Bosworth Mews, Bournemouth, Dorset BH9 3SD (GB). **SEDDON, James, Killingworth**; 5 Nuthatch Close, Ferndown, Dorset BH22 9QJ (GB).
- (74) Agents: **WELCH, Gerald T.** et al.; Harness Dickey & Pierce, P.L.C., 5445 Corporate Drive, Suite 200, Troy, TX 48098 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]

(54) Title: NEGATIVE-PRESSURE THERAPY WITH PNEUMATICALLY-ACTUATED INSTILLATION



(57) Abstract: New and useful systems, apparatuses, and methods for providing negative-pressure therapy with instillation of topical treatment solutions are described. An apparatus may comprise an exudate container, a solution source, and a pneumatically-actuated instillation regulator. The instillation regulator may be coupled to the exudate container and to the solution source, and negative pressure from a negative -pressure source can actuate the instillation regulator. In some embodiments, a negative -pressure source may be configured for a negative-pressure interval and a venting interval, and the instillation regulator can be configured to draw instillation solution from the solution source during a negative-pressure interval and to instill the solution to a dressing during a venting interval.

WO 2016/065335 A1

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
- Published:**
- *with international search report (Art. 21(3))*
 - *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

NEGATIVE-PRESSURE THERAPY WITH PNEUMATICALLY-ACTUATED INSTILLATION

TECHNICAL FIELD

[0001] The invention set forth in the appended claims relates generally to tissue treatment systems and more particularly, but without limitation, to apparatuses and methods for providing negative-pressure therapy with instillation of topical treatment solutions.

BACKGROUND

[0002] Clinical studies and practice have shown that reducing pressure in proximity to a tissue site can augment and accelerate growth of new tissue at the tissue site. The applications of this phenomenon are numerous, but it has proven particularly advantageous for treating wounds. Regardless of the etiology of a wound, whether trauma, surgery, or another cause, proper care of a wound is important to the outcome. Treatment of wounds or other tissue with reduced pressure may be commonly referred to as "negative-pressure therapy," but is also known by other names, including "negative-pressure wound therapy," "reduced-pressure therapy," "vacuum therapy," "vacuum-assisted closure," and "topical negative-pressure," for example. Negative-pressure therapy may provide a number of benefits, including migration of epithelial and subcutaneous tissues, improved blood flow, and micro-deformation of tissue at a wound site. Together, these benefits can increase development of granulation tissue and reduce healing times.

[0003] There is also widespread acceptance that cleansing a tissue site can be highly beneficial for new tissue growth. For example, a wound can be washed out with a stream of liquid solution, or a cavity can be washed out using a liquid solution for therapeutic purposes. These practices are commonly referred to as "irrigation" and "lavage" respectively. "Instillation" is another practice that generally refers to a process of slowly introducing fluid to a tissue site and leaving the fluid for a prescribed period of time before removing the fluid. For example, instillation of topical treatment solutions over a wound bed can be combined with negative-pressure therapy to further promote wound healing by loosening soluble contaminants in a wound bed and removing infectious material. As a result, soluble bacterial burden can be decreased, contaminants removed, and the wound cleansed.

[0004] While the clinical benefits of negative-pressure therapy and instillation are widely known, the cost and complexity of negative-pressure therapy can be a limiting factor in its application, and the development and operation of negative-pressure systems, components, and processes continues to present significant challenges to manufacturers, healthcare providers, and patients.

BRIEF SUMMARY

[0005] New and useful systems, apparatuses, and methods for providing negative-pressure therapy with instillation of topical treatment solutions are set forth in the appended claims. Illustrative embodiments are also provided to enable a person skilled in the art to make and use the claimed subject matter.

[0006] For example, an apparatus is described herein that may comprise an exudate container, a solution source, and an instillation regulator that can be pneumatically-actuated. The instillation regulator may be coupled to the exudate container and to the solution source, and negative pressure from a negative-pressure source can actuate the instillation regulator. In some embodiments, for example, a negative-pressure source may be configured for a negative-pressure interval and a venting interval, and the instillation regulator can be configured to draw instillation solution from the solution source during a negative-pressure interval and to instill the solution to a dressing during a venting interval.

[0007] In more particular example embodiments, the instillation regulator may have a solution inlet port, a solution outlet port, and a negative-pressure port. The solution inlet port may be fluidly coupled to a solution source, and the solution outlet port may be fluidly coupled to a dressing. The negative-pressure port may be fluidly coupled to a negative-pressure source, which can provide negative pressure through the negative-pressure port to actuate the instillation regulator.

[0008] In some example embodiments, the instillation regulator may include a piston disposed within a housing. The piston may partition the housing into a first chamber and a second chamber. The solution inlet port may be fluidly coupled to the solution source and to the first chamber. The solution outlet port may be fluidly coupled to a dressing and to the first chamber. The negative-pressure port may fluidly couple a negative-pressure source to the second chamber, so that negative pressure applied to the second chamber through the negative-pressure port during a negative-pressure interval can actuate the piston. For example, if negative pressure is applied to the second chamber, the pressure differential across the piston can move the piston within the housing, increasing the volume of the first chamber and decreasing the volume of the second chamber. An increase in the volume of the first chamber can decrease the pressure in the first chamber, drawing instillation solution from the solution source through the solution inlet port and into the first chamber. If the pressure in the second chamber is increased, such as during a venting interval, the pressure

differential across the piston can reverse the movement of the piston to decrease the volume of the first chamber and increase the volume of the second chamber. Decreasing the volume of the first chamber can increase the pressure in the first chamber, expelling instillation solution from the first chamber through the solution outlet port. Check valves can be coupled to the solution inlet port and the solution outlet port to prevent drawing fluid through the solution outlet port and expelling fluid through the solution inlet port.

[0009] In some embodiments, the instillation regulator may be disposed within an exudate container. For example, the instillation regulator may be integrally molded with an exudate container or may be mounted to an interior surface of an exudate container. In yet other example embodiments, the instillation regulator may be configured for coupling between an exudate container and a negative-pressure source.

[0010] In some embodiments, instillation solution may be managed as an ancillary to an exudate container, but in other embodiments the instillation solution may be managed integrally to the exudate canister. For example, in some embodiments, a solution source may be externally mounted on an exudate container, but in other example embodiments, a solution source may be disposed within an exudate container.

[0011] An apparatus having some or all of these illustrative features may also be used in a system for providing negative-pressure therapy with instillation of topical treatment solutions. For example, a system for treating a tissue site with negative-pressure and instillation therapy may include a dressing, an exudate container, and a negative-pressure source fluidly coupled to the dressing and the exudate container. The system may also include a source of instillation solution. An instillation regulator may be fluidly coupled to the solution source and to the negative-pressure source. Negative pressure from the negative-pressure source can actuate the instillation regulator to draw solution from the solution source. Venting the negative pressure can actuate the instillation regulator to instill the solution to the dressing.

[0012] In yet other embodiments, a method for treating a tissue site with negative pressure and topical instillation solution is also describe. For example, a dressing may be applied to the tissue site and coupled to a negative-pressure source. An instillation regulator may also be fluidly coupled to the negative-pressure source and to the dressing. A source of instillation solution may be coupled to the instillation regulator. Solution may be drawn to the instillation regulator from the solution source during a negative-pressure interval, and

solution may be instilled from the instillation regulator to the dressing during a venting interval.

[0013] Objectives, advantages, and a preferred mode of making and using the claimed subject matter may be understood best by reference to the accompanying drawings in conjunction with the following detailed description of illustrative embodiments.

BRIEF DESCRIPTION OF THE DRAWINGS

[0014] Figure 1 is a functional block diagram of an example embodiment of a therapy system that can provide negative-pressure therapy and instillation in accordance with this specification;

[0015] Figure 2 is a perspective view illustrating additional details that may be associated with some example embodiments of an instillation regulator in the therapy system of Figure 1;

[0016] Figures 3A-3B are assembly views illustrating additional details that may be associated with some embodiments of the instillation regulator of Figure 2;

[0017] Figure 4 is a top view illustrating additional details that may be associated with some embodiments of the instillation regulator of Figure 2;

[0018] Figure 5A is a cross-section of the instillation regulator shown in Figure 4 taken along line 5A-5A;

[0019] Figure 5B is a cross-section of the instillation regulator shown in Figure 4 taken along line 5B-5B;

[0020] Figure 6 is a perspective view illustrating additional details of another example embodiment of an instillation regulator that may be associated with the therapy system of Figure 1;

[0021] Figures 7A-7B are assembly views illustrating additional details that may be associated with some embodiments of the instillation regulator of Figure 6;

[0022] Figure 8 is a top view illustrating additional details that may be associated with some embodiments of the instillation regulator of Figure 6;

[0023] Figure 9A is a cross-section of the instillation regulator shown in Figure 8 taken along line 9A-9A;

[0024] Figure 9B is a cross-section of the instillation regulator shown in Figure 8 taken along line 9B-9B;

[0025] Figure 9C is a cross-section of the instillation regulator shown in Figure 8 taken along line 9C-9C;

[0026] Figure 10 is a schematic diagram illustrating an example embodiment of a fluid management system comprising an instillation regulator disposed within an exudate container;

[0027] Figure 11 is a schematic diagram illustrating another example embodiment of a fluid management system comprising the instillation regulator of Figure 10 disposed within an exudate container;

[0028] Figure 12 is a schematic diagram illustrating another alternative embodiment of a fluid management system;

[0029] Figure 13 is a schematic diagram illustrating another alternative embodiment of a fluid management system;

[0030] Figure 14 is a schematic diagram illustrating yet another example embodiment of a fluid management system; and

[0031] Figure 15 is a schematic diagram illustrating additional details that may be associated with some embodiments of a fluid management system.

DESCRIPTION OF EXAMPLE EMBODIMENTS

[0032] The following description of example embodiments provides information that enables a person skilled in the art to make and use the subject matter set forth in the appended claims, but may omit certain details already well-known in the art. The following detailed description is, therefore, to be taken as illustrative and not limiting.

[0033] The example embodiments may also be described herein with reference to spatial relationships between various elements or to the spatial orientation of various elements depicted in the attached drawings. In general, such relationships or orientation assume a frame of reference consistent with or relative to a patient in a position to receive treatment. However, as should be recognized by those skilled in the art, this frame of reference is merely a descriptive expedient rather than a strict prescription.

[0034] Figure 1 is a simplified block diagram of an example embodiment of a therapy system 100 that can provide negative-pressure therapy with instillation of topical treatment solutions in accordance with this specification. The therapy system 100 may include a dressing and a negative-pressure source. For example, a dressing 102 may be fluidly coupled to a negative-pressure source 104, as illustrated in Figure 1. A regulator, such as a pressure regulator 106, may also be fluidly coupled to the dressing 102 and the negative-pressure source 104. A dressing may include a cover and a tissue interface. The dressing 102, for example, may include a cover 108 and a tissue interface 110. The therapy system 100 may also include an exudate container, such as a container 112, coupled to the dressing 102 and to the negative-pressure source 104.

[0035] The therapy system 100 may also include a source of instillation solution. For example, a solution source 114 may be fluidly coupled to the dressing 102, as illustrated in the example embodiment of Figure 1. A second regulator, such as an instillation regulator 116, may be fluidly coupled to the solution source 114 and the dressing 102. In some embodiments, the instillation regulator 116 may also be pneumatically coupled to the negative-pressure source 104, as illustrated in the example of Figure 1. The instillation regulator 116 may also be integrated with the container 112 in some embodiments to provide a single, disposable product.

[0036] In general, components of the therapy system 100 may be coupled directly or indirectly. For example, the negative-pressure source 104 may be directly coupled to the pressure regulator 106 and indirectly coupled to the dressing 102 through the pressure

regulator 106. In some embodiments, components may be coupled by virtue of physical proximity, being integral to a single structure, or being formed from the same piece of material. Coupling may also include mechanical, thermal, electrical, or chemical coupling (such as a chemical bond) in some contexts.

[0037] Components may be fluidly coupled to each other to provide a path for transferring fluids (i.e., liquid and/or gas) between the components. In some embodiments, for example, components may be fluidly coupled through a tube. A “tube,” as used herein, broadly refers to a tube, pipe, hose, conduit, or other fluid conductor with one or more lumina adapted to convey fluid between two ends. Typically, a tube is an elongated, cylindrical structure with some flexibility, but the geometry and rigidity may vary. A fluid conductor may also be integrally molded into a component in some embodiments.

[0038] In operation, the tissue interface 110 may be placed within, over, on, or otherwise proximate to a tissue site. The cover 108 may be placed over the tissue interface 110 and sealed to tissue near the tissue site. For example, the cover 108 may be sealed to undamaged epidermis peripheral to a tissue site. Thus, the dressing 102 can provide a sealed therapeutic environment proximate to a tissue site, substantially isolated from the external environment, and the negative-pressure source 104 can reduce the pressure in the sealed therapeutic environment. Negative pressure applied across a tissue site through the tissue interface 110 in the sealed therapeutic environment can induce macro-strain and micro-strain in the tissue site, as well as remove exudate and other fluid from the tissue site, which can be collected in the container 112 and disposed of properly.

[0039] The fluid mechanics of using a negative-pressure source to reduce pressure in another component or location, such as within a sealed therapeutic environment, can be mathematically complex. However, the basic principles of fluid mechanics applicable to negative-pressure therapy and instillation are generally well-known to those skilled in the art.

[0040] In general, fluid flows toward lower pressure along a fluid path. Thus, the term “downstream” typically implies something in a fluid path relatively closer to a source of negative pressure or further away from a source of positive pressure; conversely, the term “upstream” implies something relatively further away from a source of negative pressure or closer to a source of positive pressure. Similarly, it may be convenient to describe certain features in terms of fluid “inlet” or “outlet” in such a frame of reference, and the process of reducing pressure may be described illustratively herein as “delivering,” “distributing,” or

“generating” reduced pressure, for example. This orientation is generally presumed for purposes of describing various features and components herein.

[0041] The term “tissue site” in this context broadly refers to a wound or defect located on or within tissue, including but not limited to, bone tissue, adipose tissue, muscle tissue, neural tissue, dermal tissue, vascular tissue, connective tissue, cartilage, tendons, or ligaments. A wound may include chronic, acute, traumatic, subacute, and dehisced wounds, partial-thickness burns, ulcers (such as diabetic, pressure, or venous insufficiency ulcers), flaps, and grafts, for example. The term “tissue site” may also refer to areas of any tissue that are not necessarily wounded or defective, but are instead areas in which it may be desirable to add or promote the growth of additional tissue. For example, negative pressure may be used in certain tissue areas to grow additional tissue that may be harvested and transplanted to another tissue location.

[0042] “Negative pressure” generally refers to a pressure less than a local ambient pressure, such as the ambient pressure in a local environment external to a sealed therapeutic environment provided by the dressing 102. In many cases, the local ambient pressure may also be the atmospheric pressure at which a tissue site is located. Alternatively, negative pressure may be a pressure less than a hydrostatic pressure associated with tissue at the tissue site. Unless otherwise indicated, values of pressure stated herein are gauge pressures. Similarly, references to increases in negative pressure typically refer to a decrease in absolute pressure, while decreases in negative pressure typically refer to an increase in absolute pressure.

[0043] A negative-pressure source, such as the negative-pressure source 104, may be a reservoir of air at a negative pressure, or may be a manual or electrically-powered device that can reduce the pressure in a sealed volume, such as a vacuum pump, a suction pump, a wall suction port available at many healthcare facilities, or a micro-pump, for example. A negative-pressure source may be housed within or used in conjunction with other components, such as sensors, processing units, alarm indicators, memory, databases, software, display devices, or user interfaces that further facilitate negative-pressure therapy. While the amount and nature of negative pressure applied to a tissue site may vary according to therapeutic requirements, the pressure is generally a low vacuum, also commonly referred to as a rough vacuum, between -5 mm Hg (-667 Pa) and -500 mm Hg (-66.7 kPa). Common therapeutic ranges are between -75 mm Hg (-9.9 kPa) and -300 mm Hg (-39.9 kPa). In some

embodiments, negative pressure may be applied intermittently or periodically, with intervals of negative-pressure and intervals of venting or positive-pressure.

[0044] The tissue interface 110 can be generally adapted to contact a tissue site. The tissue interface 110 may be partially or fully in contact with a tissue site. If a tissue site is a wound, for example, the tissue interface 110 may partially or completely fill the wound, or may be placed over the wound. The tissue interface 110 may take many forms, and may have many sizes, shapes, or thicknesses depending on a variety of factors, such as the type of treatment being implemented or the nature and size of a tissue site. For example, the size and shape of the tissue interface 110 may be adapted to the contours of deep and irregular shaped tissue sites. In some embodiments, the tissue interface may be provided in a spiral cut sheet. Moreover, any or all of the surfaces of the tissue interface 110 may have an uneven, coarse, or jagged profile that can induce micro-strains and stresses at a tissue site.

[0045] In some embodiments, the tissue interface 110 may be a manifold. A "manifold" in this context generally includes any substance or structure providing a plurality of pathways adapted to collect or distribute fluid across a tissue site. For example, a manifold may be adapted to receive negative pressure from a source and distribute negative pressure through multiple apertures across a tissue site, which may have the effect of collecting fluid from across a tissue site and drawing the fluid toward the source. In some embodiments, the fluid path may be reversed or a secondary fluid path may be provided to facilitate distributing fluid across a tissue site.

[0046] In some illustrative embodiments, the pathways of a manifold may be interconnected to improve distribution or collection of fluids across a tissue site. For example, cellular foam, open-cell foam, reticulated foam, porous tissue collections, and other porous material such as gauze or felted mat generally include pores, edges, and/or walls adapted to form interconnected fluid pathways. Liquids, gels, and other foams may also include or be cured to include apertures and fluid pathways. In some illustrative embodiments, a manifold may be a porous foam material having interconnected cells or pores adapted to distribute negative pressure across a tissue site. The foam material may be either hydrophobic or hydrophilic. The pore size of a foam material may vary according to needs of a prescribed therapy. For example, in some embodiments, the tissue interface 110 may be a foam having pore sizes in a range of 400-600 microns. The tensile strength of the tissue interface 110 may also vary according to needs of a prescribed therapy. For example, the tensile strength of a foam may be increased for instillation of topical treatment solutions. In

one non-limiting example, the tissue interface 110 may be an open-cell, reticulated polyurethane foam such as GranuFoam[®] dressing available from Kinetic Concepts, Inc. of San Antonio, Texas; in other embodiments the tissue interface 110 may be an open-cell, reticulated polyurethane foam such as a VeraFlo[®] foam, also available from Kinetic Concepts, Inc., of San Antonio, Texas.

[0047] In an example in which the tissue interface 110 may be made from a hydrophilic material, the tissue interface 110 may also wick fluid away from a tissue site, while continuing to distribute negative pressure to the tissue site. The wicking properties of the tissue interface 110 may draw fluid away from a tissue site by capillary flow or other wicking mechanisms. An example of a hydrophilic foam is a polyvinyl alcohol, open-cell foam such as V.A.C. WhiteFoam[®] dressing available from Kinetic Concepts, Inc. of San Antonio, Texas. Other hydrophilic foams may include those made from polyether. Other foams that may exhibit hydrophilic characteristics include hydrophobic foams that have been treated or coated to provide hydrophilicity.

[0048] In some embodiments, the tissue interface 110 may be constructed from bioresorbable materials. Suitable bioresorbable materials may include, without limitation, a polymeric blend of polylactic acid (PLA) and polyglycolic acid (PGA). The polymeric blend may also include without limitation polycarbonates, polyfumarates, and caprolactones. The tissue interface 110 may further serve as a scaffold for new cell-growth, or a scaffold material may be used in conjunction with the tissue interface 110 to promote cell-growth. A scaffold is generally a substance or structure used to enhance or promote the growth of cells or formation of tissue, such as a three-dimensional porous structure that provides a template for cell growth. Illustrative examples of scaffold materials include calcium phosphate, collagen, PLA/PGA, coral hydroxy apatites, carbonates, or processed allograft materials.

[0049] In some embodiments, the cover 108 may provide a bacterial barrier and protection from physical trauma. The cover 108 may also be constructed from a material that can reduce evaporative losses and provide a fluid seal between two components or two environments, such as between a therapeutic environment and a local external environment. The cover 108 may be, for example, an elastomeric film or membrane that can provide a seal adequate to maintain a negative pressure at a tissue site for a given negative-pressure source. In some example embodiments, the cover 108 may be a polymer drape, such as a polyurethane film, that is permeable to water vapor but impermeable to liquid. Such drapes typically have a thickness in the range of 25-50 microns. For permeable materials, the

permeability generally should be low enough that a desired negative pressure may be maintained.

[0050] An attachment device may be used to attach the cover 108 to an attachment surface, such as undamaged epidermis, a gasket, or another cover. The attachment device may take many forms. For example, an attachment device may be a medically-acceptable, pressure-sensitive adhesive that extends about a periphery, a portion, or an entirety of the cover 108. In some embodiments, for example, some or all of the cover 108 may be coated with an acrylic adhesive having a coating weight between 25-65 grams per square meter (g.s.m.). Thicker adhesives, or combinations of adhesives, may be applied in some embodiments to improve the seal and reduce leaks. Other example embodiments of an attachment device may include a double-sided tape, paste, hydrocolloid, hydrogel, silicone gel, or organogel.

[0051] In some embodiments, the dressing 102 may also include a fluid interface configured to fluidly couple the negative-pressure source 104 to the sealed therapeutic environment formed by the cover 108. In some embodiments, the fluid interface may include a flange portion that couples to the cover 108 and a portion that fluidly couples to a tube 120. In one exemplary embodiment, the fluid interface may be a T.R.A.C.® Pad or Sensa T.R.A.C.® Pad available from Kinetic Concepts, Inc. of San Antonio, Texas. In other exemplary embodiments, a tube may be inserted through the cover 108. Such a fluid interface can allow negative pressure to be delivered to the sealed therapeutic environment. For example, a fluid interface can provide a fluid conductor through the cover 108 to the tissue interface 110. In some embodiments, a fluid interface can also provide more than one fluid path through the cover 108 or merge more than fluid conductor into a single fluid path. For example, in some embodiments, a fluid interface can be fluidly coupled to both the negative-pressure source 104 and to the instillation regulator 116. In one embodiment, such a fluid interface may provide a separate fluid path through the cover 108 for each of the negative-pressure source 104 and the instillation regulator 116. In other embodiments, the fluid interface may merge separate fluid paths from the negative-pressure source 104 and the instillation regulator 116 into a single fluid path through the cover 108.

[0052] The container 112 is representative of a container, canister, pouch, or other storage component, which can be used to manage exudate and other fluid withdrawn from a tissue site. In many environments, a rigid container may be preferred or required for collecting, storing, and disposing of fluid. In other environments, fluid may be properly

disposed of without rigid container storage, and a re-usable container could reduce waste and costs associated with negative-pressure therapy.

[0053] The solution source 114 may also be representative of a container, canister, pouch, bag, or other storage component, which can provide a solution for instillation therapy. Compositions of solutions may vary according to a prescribed therapy, but examples of solutions that may be suitable for some prescriptions include hypochlorite-based solutions, silver nitrate (0.5%), sulfur-based solutions, biguanides, cationic solutions, and isotonic solutions.

[0054] Figure 2 is a perspective view of an instillation regulator 200 illustrating additional details that may be associated with some embodiments of the therapy system 100. The instillation regulator 200 may be an example embodiment of the instillation regulator 116 of Figure 1. The instillation regulator 200 generally includes a housing, which may be formed by a body 202 and a head 204 coupled to the body 202, as shown in the example embodiment of Figure 2. Some embodiments of the head 204 may include an extension 205. In some embodiments, the body 202 may include a flange 206, and the head 204 may include a flange 208. The body 202 may be cylindrical in some embodiments, as illustrated in the example of Figure 2, and the head 204 may be circular with a cylindrical extension 205, also as illustrated in the example of Figure 2. The flange 206 and the flange 208 may be coupled with fasteners 210, or may be coupled with other mechanical, thermal, electrical, or chemical couplings. The dimensions of the flange 208 may be similar to the dimensions of the flange 206 to facilitate a secure coupling.

[0055] Some embodiments of the instillation regulator 200 may have fluid ports adapted for coupling to fluid conductor, such as a tube. For example, as shown in Figure 2, the body 202 may have a negative-pressure port 212, and the head 204 may have a solution inlet port 214 and a solution outlet port 216. A retention cap 218 may also be coupled to the head 204 in some embodiments of the instillation regulator 200, and the body 202 may additionally comprise a vent 220, as shown in the example embodiment of Figure 2.

[0056] Figure 3A and Figure 3B are assembly views illustrating additional details that may be associated with some embodiments of an instillation regulator, such as the instillation regulator 200 of Figure 2. For example, some embodiments of the instillation regulator 200 may include a piston, an elastic device, and a gasket. A piston can be a flexible or movable barrier, for example, illustrated in Figure 3A as a piston 302. An elastic device may be a spring or rubber, for example, illustrated in Figure 3A as a spring 304. The spring 304 may

be disposed within a cavity 306 of the body 202, generally between the piston 302 and the body 202, as illustrated in the example embodiment of Figure 3A. In some embodiments, the spring 304 may be a coil spring coaxial with the piston 302, as shown in the example of Figure 3A. Also as shown in the example embodiment of Figure 3A and Figure 3B, the cavity 306 may be cylindrical, and the piston 302 may be rounded to fit within the cavity 306 of the body 202. The piston 302 may also reciprocate within the cavity 306. A gasket 308 may be disposed between the flange 206 and the flange 208.

[0057] The instillation regulator 200 may also include an outlet check valve 309 disposed between the head 204 and the retention cap 218. For example, as shown in the illustrative embodiment of Figure 3A, some embodiments of the outlet check valve 309 may be a diaphragm valve having a diaphragm 310 and an elastic device such as a spring 312. The diaphragm 310 may be a flexible membrane or partition, such as a thin flexible disk. The spring 312 may be disposed within the extension 205 over a retention boss 314, which can restrict lateral movement of the spring 312.

[0058] Some embodiments of the instillation regulator 200 may further include a flow limiter. For example, a flow limiter may comprise a hydrophobic filter 316 and a retaining ring 318, as illustrated in Figure 3A and Figure 3B. The hydrophobic filter 316 is generally configured to be disposed in or otherwise engage the vent 220, and the retaining ring 318 may be disposed around or otherwise coupled to the hydrophobic filter and the vent 220 to secure the hydrophobic filter 316 to the vent 220. In some embodiments, a flow limiter may comprise an adjustable valve, such as a needle valve.

[0059] The head 204 may include a passage configured to fluidly couple the extension 205 and the solution outlet port 216. For example, the passage may be formed by a membrane 320 coupled to the head 204 to enclose a channel 322 formed in the head 204.

[0060] In some embodiments, the piston 302 may comprise a flexible seal disposed between a base and a retainer. For example, the piston 302 of Figure 3A and Figure 3B includes a seal 324, a seal base 326, and a seal retainer 328. The seal 324 may be an elastomer or other flexible material, for example, while the seal base 326 and the seal retainer 328 preferably provide strength and rigidity to support the seal 324. In some embodiments, the seal base 326 and the seal retainer 328 may include ribs 330 to provide further structural support. The seal base 326 may include one or more alignment pins 332, which can be configured to engage one or more alignment guides 334.

[0061] Figure 4 is a top view illustrating additional details that may be associated with some embodiments of an instillation regulator, such as the instillation regulator 200. As shown in the example embodiment of Figure 4, the retention cap 218 may be vented to expose the diaphragm 310 to the ambient environment. In some embodiments, for example, the retention cap 218 may comprise a support ring 402 and cross-bars 404 coupled to the support ring 402. The cross-bars 404 are generally configured to protect the diaphragm 310 and provide a fluid path between the diaphragm 310 and the ambient environment. Additionally or alternatively, a grid, a mesh, or other suitable porous structure may be coupled to the support ring to provide similar protection and fluid communication. The solution inlet port 214 and the solution outlet port 216 may be disposed on, in, or through the head 204, adjacent to the retention cap 218 and outside the support ring 402.

[0062] Figure 5A is a sectional view of the instillation regulator 200 of Figure 4 taken on line 5A-5A, illustrating additional details that may be associated with some embodiments of the instillation regulator 200 in a first state. Figure 5B is a sectional view of the instillation regulator 200 of Figure 4 taken on line 5B-5B, illustrating additional details that may be associated with some embodiments of the instillation regulator 200 in a second state. Assembled as shown in the example embodiment of Figure 5A, the head 204 can be coupled to the body 202 to enclose the piston 302 and fluidly isolate the cavity 306 from the ambient environment. The piston 302 may partition or separate the cavity 306 into a first chamber 502 and a second chamber 504. Moreover, the piston 302 may engage the body 202 to provide a seal between the first chamber 502 and the second chamber 504. For example, as shown in the example embodiment of Figure 5A and Figure 5B, the seal 324 may press against a side wall of the body 202 to fluidly isolate the first chamber 502 from the second chamber 504.

[0063] The diaphragm 310 may be coupled to the extension 205 to form a third chamber 506, generally defined by a portion of the head 204, the extension 205, and the diaphragm 310. The spring 312 may be disposed in the third chamber 506 between the diaphragm 310 and the head 204. For example, the spring 312 may be disposed around the retention boss 314, as shown in the instillation regulator 200 of Figure 5A and Figure 5B. In some embodiments, a peripheral edge of the diaphragm 310 may be supported by the extension 205, and an interior portion of the diaphragm 310 may engage the spring 312. The retention cap 218 may be coupled to the head 204 to secure the peripheral edge of the diaphragm 310 between the retention cap 218 and the extension 205. A passage 508 through

the retention boss 314 can fluidly couple the first chamber 502 and the third chamber 506 through the outlet check valve 309. A passage 510 in the head 204 may also fluidly couple the third chamber 506 to the solution outlet port 216. The passage 508 and the passage 510 can provide a fluid path between the first chamber 502 and the solution outlet port 216 through the outlet check valve 309, which may be configured to be closed by negative pressure in the first chamber 502.

[0064] Some embodiments of the regulator 200 may also include an inlet check valve 512 and an outlet check valve 514. The inlet check valve 512 may be fluidly coupled to the first chamber 502 and configured to be opened by negative pressure in the first chamber 502. The outlet check valve 514 may be fluidly coupled to the second chamber 504 and configured to be opened by negative pressure delivered to the negative-pressure port 212 or by an increase in pressure in the second chamber 504. For example, the inlet check valve 512 may be disposed between the solution inlet port 214 and the first chamber 502, and the outlet check valve 514 may be disposed between the negative-pressure port 212 and the second chamber 504.

[0065] The spring 304 may be disposed in the second chamber 504 against the piston 302 and the body 202 to bias the piston. For example, as shown in the illustrative embodiment of Figure 5A and Figure 5B, the piston spring 516 may have a first end disposed around a retention boss 518 to restrict lateral movement, and may have a second end engaged to the piston 302. In this example configuration, the spring 304 may bias the piston toward the head 204.

[0066] Figure 6 is a perspective view of an instillation regulator 600, illustrating details that may be associated with another example embodiment of the instillation regulator 116. The instillation regulator 600 generally includes a housing, which may be formed by a body 602 and a cap 604 coupled to the body 602, as shown in the example embodiment of Figure 6. Some embodiments of the instillation regulator 600 may have fluid ports adapted for coupling to a tube or other fluid conductor. For example, as shown in Figure 6, the instillation regulator 600 may have a first fluid port, such as the solution inlet port 606, which may extend through an inlet port opening 610 of the cap 604, and a second fluid port, such as the solution outlet port 608, which may extend through an outlet port opening 612.

[0067] Figure 7A and Figure 7B are assembly views illustrating additional details that may be associated with some embodiments of an instillation regulator, such as the instillation regulator 600 of Figure 6. Some embodiments of the instillation regulator 600 may include a

piston, an elastic device, and a gasket. The piston can be a flexible or movable barrier, for example, illustrated in Figure 7A as a piston 702. An elastic device may be a spring or rubber, for example, illustrated in Figure 7A as a spring 704. The spring 704 may be disposed within a cavity 706 of the body 602 of the instillation regulator 600, generally between the piston 702 and the body 602, as illustrated in the example embodiment of Figure 7B. In some embodiments, the spring 704 may be a coil spring coaxial with the piston 702, as shown in the example of Figure 7A. Also as shown in the example embodiment of Figure 7A and Figure 7B, the cavity 706 may be a cylindrical bore, and the piston 702 may be rounded to fit within the cavity 706 of the body 602. The piston 702 may also reciprocate within the cavity 706.

[0068] The body 602 of the instillation regulator 600 may also comprise a window 738, which may allow viewing the interior of the instillation regulator 600 through an opening 740. For example, the position of the piston 702 or the fluid in the cavity 706 may be viewed through the window 738 and the opening 740 in some embodiments.

[0069] The instillation regulator 600 may also include a head 708, which may be disposed between the body 602 and the cap 604. The instillation regulator 600 may also include an outlet check valve 710 disposed between the head 708 and the cap 604. For example, the outlet check valve 710 may be a diaphragm valve comprising a flexible membrane or partition, such as a thin flexible disk. A membrane 736 may also be disposed between the cap 604 and a channel 727 of the head 708. The head 708 may comprise an extension 705, and a valve seat 730 within the extension 705 configured to engage the outlet check valve 710.

[0070] Some embodiments of the instillation regulator 600 may also include a flow limiter. For example, a flow limiter may comprise a hydrophobic filter 716, as illustrated in Figure 7A and Figure 7B. The hydrophobic filter 716 is generally configured to be disposed in or otherwise engage a vent 719, and a retaining ring 717 may be disposed around or otherwise coupled to the hydrophobic filter 716 and the vent 719 to couple the hydrophobic filter 716 to the vent 719. The retaining ring 717 may be coupled to or integral with a sealing membrane 718, as illustrated in the example embodiment of Figure 7A and Figure 7B.

[0071] The head 708 may also include a passage configured to fluidly couple the valve seat 730 to the solution outlet port 608. For example, an integrated fluid conductor may be formed by a membrane 720 coupled to the head 708 to enclose a channel 712 formed in the head 708. Another passage may fluidly couple the solution outlet port 608 to the

channel 727. For example, an integrated fluid conductor may be formed by coupling the membrane 720 to the head 708 to enclose a channel 714. The membrane 736 may also be coupled to the head 708 to enclose the channel 727. In some embodiments, any or all of the channel 712, the channel 714 and the channel 727 may be integrally molded into the head 708.

[0072] The body 602 may also include one or more passages configured to fluidly couple the channel 727 to the cavity 706. For example, the body 602 may include a fluid conductor formed by the sealing membrane 718 coupled to the body 602 to enclose a channel 723, and a passage 722 in the body 602 may fluidly couple the channel 723 and the channel 727. In some embodiments, either or both of the passage 722 and the channel 723 may be integrally molded in the body 602.

[0073] In some embodiments, the piston 702 may comprise a conformable seal disposed between a base and a retainer. For example, the piston 702 of Figure 7A and Figure 7B includes a seal 724, a seal base 726, and a seal retainer 728. The seal 724 may be an elastomer or other flexible material, for example, while the seal base 726 and the seal retainer 728 may be a rigid plastic to provide strength and rigidity to support the seal 724. An inlet check valve 742 may also be disposed between the head 708 and the seal retainer 728, fluidly coupled to the solution inlet port 606.

[0074] Figure 8 is a top view illustrating additional details that may be associated with some embodiments of an instillation regulator, such as the instillation regulator 600. As illustrated in the example embodiment of Figure 8, the instillation regulator 600 may have an ovate profile to accommodate the cavity 706 and the passage 722.

[0075] Figure 9A is a sectional view of the instillation regulator 600 of Figure 8 taken on line 9A-9A, illustrating additional details that may be associated with some embodiments of the instillation regulator 600. Figure 9B is a sectional view of the instillation regulator 600 of Figure 8 taken on line 9B-9B, illustrating additional details that may be associated with some embodiments of the instillation regulator 600. Figure 9C is a sectional view of the instillation regulator 600 of Figure 8 taken on line 9C-9C, illustrating additional details that may be associated with some embodiments of the instillation regulator 600. Assembled as shown in the example embodiment of Figure 9A, the head 708 can be coupled to the body 602 to fluidly isolate the cavity 706 from the ambient environment, and the piston 702 may partition or separate the cavity 706 into a first chamber 902 and a second chamber 904. Moreover, the piston 702 may engage the body 602 to provide a seal between the first

chamber 902 and the second chamber 904. For example, as shown in the example embodiment of Figure 9A, the seal 724 may press against a side wall of the body 602 to fluidly isolate the first chamber 902 from the second chamber 904.

[0076] The outlet check valve 710 may be coupled to the extension 705 to form a third chamber 924, generally defined by a portion of the head 708, the extension 705, and the outlet check valve 710. In some embodiments, a peripheral edge of the outlet check valve 710 may be supported or coupled to the extension 705. Additionally or alternatively, the cap 604 can be disposed on the head 708 to secure the outlet check valve 710 to the extension 705. A passage through the valve seat 730 may fluidly couple the first chamber 902 and the third chamber 924. The channel 712 may also fluidly couple the third chamber 924 to the solution outlet port 608.

[0077] The inlet check valve 742 may be fluidly coupled to the first chamber 902 and configured to be opened by negative pressure in the first chamber 902. Some embodiments may also comprise an outlet check valve 710 fluidly coupled to the second chamber 904 and configured to be opened by negative pressure in the channel 723 or by an increased pressure in the second chamber 904. For example, the inlet check valve 742 may be disposed between the solution inlet port 606 and the first chamber 902, and the outlet check valve 914 may be disposed between the solution outlet port 608 and the second chamber 904.

[0078] The spring 704 may be disposed between the piston 702 and the body 602 in some embodiments. For example, as shown in the illustrative embodiment of Figures 9A-9C, the spring 704 may have a first end disposed around a retention boss 918 to restrict lateral movement, and may have a second end engaged to the piston 702.

[0079] In operation, the instillation regulator 600 may be primed during negative-pressure intervals, and may instill a solution during venting intervals. For example, during a negative-pressure interval, negative pressure can be supplied by a negative-pressure therapy unit (not shown) and delivered by a tube 912 to the instillation regulator 600. In the embodiment of Figures 9A-9C, negative pressure may be delivered to the second chamber 904 through the solution outlet port 608, the passage 722, and the channel 723. Negative pressure in the second chamber 904 can move the piston 702, expanding the first chamber 902 and compressing the second chamber 904. If the first chamber 902 expands, pressure in the first chamber 902 can decrease proportionately. Negative pressure in the first chamber 902 can have the effect of actively drawing instillation solution into the first chamber 902 through the solution inlet port 606. The distance that the piston 702 travels can determine a

dosage volume of instillation solution. The first chamber 902 may be lined with a suitable material to prevent contamination from mechanical components or lubricants. For example, the first chamber 902 may be lined with a film bag, an elastomeric bag, or a compressible bellows.

[0080] In some embodiments, the instillation dosage may be adjusted. Such capability may be achieved by adjusting the distance traveled of the movable components during negative-pressure and venting intervals. For example, the spring 704 may be compressed so that the distance traveled by the piston 702 can be limited. This may result from more quickly reaching the point where the negative pressure applied to the second chamber 904 for compressing the spring 704 can no longer overcome the force exerted by the spring 704. Other example embodiments may adjust the instillation dosage by reducing the height of the second chamber 904, for example, by screwing the first chamber 902 further into the second chamber 904 using a threaded mechanism. Yet another example may include controlling the dosage of instillation fluid delivered by limiting the travel of the piston 702 within the second chamber 904 by adjusting the height of a stop block located within the second chamber 904, under the piston 702. Additional examples may include restricting the flow of instillation fluid through either the solution inflow tube 920 or the solution outflow tube 912 using, for example, a valve, or by restricting the rate at which the piston 702 recovers.

[0081] Expansion of the first chamber 902 may also have the effect of decreasing pressure in the third chamber 924, as pressure between the first chamber 902 and the third chamber 924 may be equalized through the passage 926. The decreased pressure in the third chamber 924 may have the effect of closing the outlet check valve 710, which can prevent instillation of solution to a dressing during a negative-pressure interval.

[0082] During a venting interval, the vent 719 may provide fluid communication between the second chamber 904 and the ambient environment, which can also have the effect of increasing pressure in the second chamber 904. Increased pressure in the second chamber 904 during a venting interval can have the effect of moving the piston 702, compressing the first chamber 902 and expanding the second chamber 904. If the first chamber 902 is compressed, pressure in the first chamber 902 can increase proportionately. The resulting increase in pressure can move solution out of the first chamber 902 through the valve seat 730, the channel 712, and the solution outlet port 608, instilling solution to a tissue site through the solution outflow tube 912. The inlet check valve 742 can prevent back-flow

through the solution inlet port 606 during instillation, and the outlet check valve 914 can prevent solution from moving into the second chamber 904 from the channel 723 during instillation. A flow limiter such as the hydrophobic filter 716 can control the rate of venting between the second chamber 904 and the ambient environment through the vent 719, which can also determine the rate at which the piston 702 moves and the rate at which solution can be instilled from the first chamber 902. For example, the surface area of the hydrophobic filter 716 can determine the vent rate and can be calibrated to provide a prescribed instillation rate.

[0083] Figure 10 is a schematic diagram illustrating an example embodiment of a fluid management system 1000 comprising an instillation regulator 1002 disposed within an exudate container 1004. The instillation regulator 1002 is an example embodiment of the instillation regulator 116 of Figure 1, and the exudate container 1004 may be an example embodiment of the container 112 of Figure 1. The fluid management system 1000 may also include an ancillary instillation solution source, such as a solution bag 1006. The solution bag 1006 may be an example embodiment of the solution source 114 of Figure 1. In some embodiments, the solution bag 1006 may be externally mounted on the exudate container 1004, as illustrated in Figure 10. In other embodiments, the solution bag 1006 may be secured to a pole or other hanger, preferably in close proximity to the exudate container 1004.

[0084] The instillation regulator 1002 may be analogous in many respects to the instillation regulator 200 or the instillation regulator 600. For example, the instillation regulator 1002 may include a housing 1008, a solution inlet port 1010, a solution outlet port 1012, and a negative-pressure port 1014. The instillation regulator 1002 may also include a piston 1016 disposed in a cavity of the housing 1008. The piston 1016 may partition or separate the cavity into a first chamber 1018 and a second chamber 1020. Moreover, the piston 1016 may engage the housing 1008 to provide a seal between the first chamber 1018 and the second chamber 1020. A spring 1022 may be disposed between the piston 1016 and the housing 1008, as illustrated in the example embodiment of Figure 10. The piston 1016 may reciprocate within the housing 1008, varying the volume of the first chamber 1018 and the second chamber 1020.

[0085] As illustrated in Figure 10, the instillation regulator 1002 may be disposed within an interior space of the exudate container 1004 in some embodiments. For example, the instillation regulator 1002 may be fastened to a wall of the exudate container 1004, or may be integrally molded with the exudate container 1004. The instillation regulator 1002

may also be fluidly coupled to the solution bag 1006, to a dressing (not shown in Figure 10), and to a negative-pressure source (not shown in Figure 10). For example, in some embodiments, the fluid management system 1000 may provide a fluid path 1026 between the solution bag 1006 and the solution inlet port 1010, a fluid path 1028 between the solution outlet port 1012 and a dressing, and a fluid path 1030 between the negative-pressure port 1014 and a negative-pressure source. The fluid path 1030 may additionally couple the negative-pressure source to the dressing through the exudate container 1004 in some embodiments.

[0086] Each of the fluid path 1026, the fluid path 1028, and the fluid path 1030 may be comprised of more than one fluid conductor, coupled together through suitable interfaces. For example, in some embodiments, the fluid path 1026 may include an integrated fluid conductor molded into the exudate container 1004. In other embodiments, the fluid path 1026 may include a tube. A fluid conductor can be coupled on a first end to the solution inlet port 1010 and terminate on a second end with an interface 1032 through the exudate container 1004. Another fluid conductor may be coupled between the interface 1032 and the solution bag 1006. In other embodiments, the fluid path 1026 may be a tube, which can be coupled on a first end to the solution inlet port 1010, exit the exudate container 1004 through the interface 1032, and be coupled or configured to be coupled on a second end to the solution bag 1006. Similarly, in some embodiments, the fluid path 1028 may include an integral fluid conductor molded into the exudate container 1004. In other embodiments, the fluid path 1028 may include a tube. A fluid conductor can be coupled on a first end to the solution outlet port 1012 and terminate on a second end with an interface 1034 through the exudate container 1004. Another tube or fluid conductor may be coupled between the interface 1034 and a dressing to complete a fluid path to the dressing. In other embodiments, the fluid path 1028 may be a tube, which can be coupled on a first end to the solution outlet port 1012, exit the exudate container 1004 through the interface 1034, and be coupled or configured to be coupled on a second end to a dressing. The fluid path 1030 may similarly include an integrated fluid conductor or a tube coupled to a negative-pressure source through an interface 1036.

[0087] Figure 11 is a schematic diagram illustrating another example embodiment of a fluid management system 1100 comprising the instillation regulator 1002 disposed within an exudate container 1104. The exudate container 1104 may be another example embodiment of the container 112 of Figure 1. In some embodiments, the instillation

regulator 1002 may be fastened to a wall of the exudate container 1104, or may be integrally molded with the exudate container 1104. The fluid management system 1100 may also include an instillation solution source, such as a syringe 1106. The syringe 1106 may be an example embodiment of the solution source 114 of Figure 1. In some embodiments, the syringe 1106 may be externally mounted on the exudate container 1104, as illustrated in Figure 10. In other embodiments, the syringe 1106 may be secured to a pole or other hanger, preferably in close proximity to the exudate container 1104. The syringe 1106 can prime the fluid management system 1100 with instillation fluid that can be obtained from other sources, such as from larger containers or from multiple containers. The syringe 1106 may also be advantageous for accurately recording dosages of instillation solution administered through the fluid management system 1100.

[0088] Figure 12 is a schematic diagram illustrating another alternative embodiment of a fluid management system 1200. The fluid management system 1200 may include the instillation regulator 1002 integrated with an exudate container 1204. The exudate container 1204 may be another example embodiment of the container 112 of Figure 1. In some embodiments, the instillation regulator 1002 may be fastened to a wall of the exudate container 1204, or may be integrally molded with the exudate container 1204. The fluid management system 1200 may also include an instillation solution source, such as a solution container 1206. The solution container 1206 may be another example embodiment of the solution source 114 of Figure 1. In some embodiments, the solution container 1206 may be integrated with the exudate container 1204 to provide a single disposable unit. For example, in some embodiments, the solution container 1206 may be a pouch comprising a suitable plastic or liquid-impermeable film welded or otherwise secured to an external surface of the exudate container 1204. In other embodiments, the solution container 1206 may be a rigid plastic integrally molded with the exudate container 1204. The fluid path 1026 may also be integrated in the exudate container 1204 in some embodiments to reduce external tubes.

[0089] Figure 13 is a schematic diagram illustrating another alternative embodiment of a fluid management system 1300. The fluid management system 1300 may include the instillation regulator 1002 disposed within an exudate container 1304. The exudate container 1304 may be an example embodiment of the container 112 of Figure 1. In some embodiments, the instillation regulator 1002 may be fastened to a wall of the exudate container 1304, or may be integrally molded with the exudate container 1304. The fluid management system 1300 may also include an instillation solution source, such as a solution

container 1306. The solution container 1306 may be an example embodiment of the solution source 114 of Figure 1. In some embodiments, the solution container 1306 may be integrated with the exudate container 1304 to provide a single disposable unit. For example, in some embodiments, the solution container 1306 may be a flexible pouch disposed within an interior space of the exudate container 1304. Disposing the solution container 1306 within the exudate container 1304 may be advantageous for transport and storage, and may also prevent tampering and use of uncontrolled instillation solution. The volume displaced by the solution container 1306 can be reduced as instillation solution is delivered to a tissue site, thereby increasing the free volume in the exudate container 1304 available for collecting exudate and used instillation solution. A non-return valve can prevent the solution container 1306 from expanding under negative pressure in the exudate container 1304.

[0090] Figure 14 is a schematic diagram illustrating yet another example embodiment of a fluid management system 1400. The fluid management system 1400 may include the instillation regulator 1002 coupled externally to an exudate container 1404. For example, in some embodiments the instillation regulator 1002 may be disposed within, integrated with, or coupled to an adapter housing 1406, which can be coupled to the exudate container 1404. The exudate container 1404 and the adapter housing 1406 may each be configured with suitable interfaces to fluidly couple the solution inlet port 1010 to an instillation solution source (not shown in Figure 14), and to fluidly couple the solution outlet port 1012 to a dressing (not shown in Figure 14). The exudate container 1404 and the adapter housing 1406 may also include suitable interfaces for fluidly coupling a negative-pressure source (not shown in Figure 14) to the negative-pressure port 1014 and to a dressing. In some embodiments, the instillation regulator 1002 or the adapter housing 1406 may be detached from the exudate container 1404 and re-used, particularly for a single patient.

[0091] Figure 15 is a schematic diagram illustrating additional details that may be associated with some embodiments of a fluid management system 1500. The fluid management system 1500 may be analogous to any of the previously described embodiments of a fluid management system, or any combination of features previously described. For example, the fluid management system 1500 may include the instillation regulator 1002 disposed within an exudate container 1504. The exudate container 1504 may be an example embodiment of the container 112 of Figure 1. In some embodiments, the instillation regulator 1002 may be fastened to a wall of the exudate container 1504, or may be integrally molded with the exudate container 1504. The fluid management system 1500 may optionally

include a means for controlling or adjusting a dosage of instillation solution. For example, a pin or adjustable lever 1506 may limit the range of motion of the piston 1016 in some embodiments. In other example embodiments, the spring rate of the spring 1022 may be increased or decreased.

[0092] Figure 16 is an assembly view illustrating an example embodiment of a fluid management system 1600. The fluid management system 1600 may include a container housing 1602, an instillation regulator 1604, a panel 1606, and a seal 1608. The container housing 1602 and the panel 1606 are preferably constructed from a material that is impermeable to fluid, such as a rigid or semi-rigid plastic. The seal 1608 preferably comprises a material that is relatively pliable and impermeable to fluid. For example, the seal 1608 may be manufactured from a non-porous polyester film, preferably having a thickness between 0.1 millimeters and 0.2 millimeters. The seal 1608 also preferably comprises an adhesive or other suitable means for attaching the seal 1608 to the panel 1606. For example, the seal 1608 may include an acrylic adhesive applied to one side, preferably having a thickness of about 0.15 millimeters. In some embodiments, the seal 1608 may be an adhesive label or integrated with product labeling.

[0093] The fluid management system 1600 may also include tubes or other fluid conductors for fluidly coupling the fluid management system 1600 to a tissue site or other components of a therapy system, such as the therapy system 100. For example, as illustrated in Figure 16, the fluid management system 1600 may include a tube 1610 for coupling the container housing 1602 to a tissue site, a tube 1612 for coupling the container housing 1602 to an instillation solution source, and another tube 1614 for coupling the container housing 1602 to a tissue site.

[0094] In some embodiments, the container housing 1602 may include fluid ports adapted for coupling to tubes or other fluid conductors. For example, the container housing 1602 may include a fluid port 1616 adapted for coupling to the tube 1610, a fluid port 1618 adapted for coupling to the tube 1612, and a fluid port 1620 adapted for coupling to the tube 1614.

[0095] In some embodiments, the instillation regulator 1604 may be similar or analogous to the instillation regulator 1002 in many respects. For example, the instillation regulator 1604 may have fluid ports, such as a solution outlet port 1622 and a solution inlet port 1624, analogous to the solution outlet port 216 and the solution inlet port 214, respectively. The instillation regulator 1604 may also have retention clips 1626 adapted to

mechanically couple the instillation regulator 1604 to the panel 1606. A tube or other fluid conductor may also be coupled to the solution outlet port 1622 and the solution inlet port 1624. For example, as illustrated in Figure 16, a tube 1628 may be coupled to the solution outlet port 1622 and a tube 1630 may be coupled to the solution inlet port 1624.

[0096] In some embodiments, the panel 1606 may also include fluid ports adapted for coupling to a tube or other fluid conductor. For example, as shown in Figure 16, the panel 1606 may include a port 1632, a port 1634, and a port 1636. A hydrophobic filter 1638 may also be coupled to or integral with some embodiments of the panel 1606.

[0097] Figure 17 is a rear view of the panel 1606 of Figure 16, illustrating additional details that may be associated with some embodiments. As illustrated in Figure 17, fluid channels may be integrated into some embodiments of the panel 1606. For example, the panel 1606 of Figure 17 may include a channel 1702, a channel 1704, and a channel 1706. In some embodiments, each of the channel 1702, the channel 1704, and the channel 1706 may be an open channel, as shown in Figure 17. Such an open channel may, for example, be formed as a groove, furrow, cut, depression, or gutter in the panel 1606. In some embodiments, an open channel may have a rectangular, semi-circular, or trapezoidal cross-section, for example. A passage through the panel 1606 may also be disposed at each terminus of the channels 1702-1706 in some embodiments. For example, a passage 1708 may be disposed at a first terminus of the channel 1702, and a passage 1710 may be disposed at a second terminus of the channel 1702. Similarly, a passage 1712 may be disposed at a first terminus of the channel 1704 and a passage 1714 may be disposed at a second terminus of the channel 1704, and a passage 1716 and a passage 1718 may be disposed at opposing ends of the channel 1706. In the example embodiment of Figure 17, some or all of the passages 1708-1718 may be fluidly coupled to a fluid port on the opposing side of the panel 1606. For example, the passage 1710 may be fluidly coupled to the port 1636, the passage 1714 may be fluidly coupled to the port 1634, and the passage 1718 may be fluidly coupled to the port 1632. The panel 1606 may include additional passages, such as a passage 1720, which can fluidly couple a first side of the panel 1606 to a second side of the panel 1606. In some embodiments, the passage 1720 can be fluidly coupled to the hydrophobic filter 1638.

[0098] The seal 1608 may be attached to the panel 1606 and cover the channels 1702-1706 to form integrated fluid conductors. For example, the seal 1608 may cover the channel 1702 to form an integrated fluid conductor between the passage 1708 and the passage 1710. The seal 1608 preferably covers and seals each of the channels 1702-1706, and each of the

channels 1702-1706 is preferably deep enough to ensure that deformation of the seal under negative pressure does not cause the seal to block the channels 1702-1706.

[0099] Figure 18 is a perspective view of an example embodiment of the assembled fluid management system 1600. As illustrated in Figure 18, the tube 1610 may be coupled to the port 1616, the tube 1612 may be coupled to the port 1618, and the tube 1614 may be coupled to the port 1620.

[00100] Figure 19 is a section view of the fluid management system 1600 taken along line 19-19 of Figure 18, illustrating additional details that may be associated with some embodiments. As shown in the example embodiment of Figure 19, the panel 1606 is preferably configured to be fastened to the container housing 1602 to enclose the instillation regulator 1604 and form an exudate container, which may be suitable for use with some embodiments of the fluid management systems previously described. In some embodiments, for example, the fluid management system 1600 may be assembled to provide fluid paths analogous to the fluid path 1026, the fluid path 1028, and the fluid path 1030.

[00101] For example, a fluid path analogous to the fluid path 1026 may be provided by coupling a first end of the tube 1612 to the port 1618, and coupling a second end of the tube 1612 to an instillation solution source, such as the solution bag 1006, the syringe 1106, or the solution container 1206. The port 1618 may provide a fluid path from the tube 1612 to the passage 1712, and the channel 1704 can provide a fluid path from the passage 1712 to the passage 1714. The passage 1714 can provide a fluid path from the channel 1704 to the port 1634. The tube 1630 can provide a fluid path between the port 1634 and the solution inlet port 1624, thereby completing a fluid path between the instillation solution source and the solution inlet port 1624.

[00102] A fluid path analogous to the fluid path 1028 may also be assembled by coupling a first end of the tube 1614 to the port 1620, and coupling a second end of the tube 1614 to a dressing, such as the dressing 102. Assembled in this exemplary configuration, the tube 1628 can provide a fluid path between the solution outlet port 1622 and the port 1632. The port 1632 can provide a fluid path between the tube 1628 and the passage 1718, which can be in fluid communication with the channel 1706. The channel 1706 can provide a fluid path between the passage 1718 and the passage 1716, which can be in fluid communication with the port 1620, thereby completing a fluid path between the solution outlet port 1622 and the tube 1614.

[00103] In some embodiments, a fluid path analogous to the fluid path 1030 may be provided by fluidly coupling the passage 1720 to a negative-pressure source, such as the negative-pressure source 104, for example. Assembled in this exemplary configuration, the passage 1720 can provide a fluid path between a negative-pressure source and the interior of the container housing 1602, preferably through the hydrophobic filter 1638. The tube 1610 may be coupled to the port 1616, which can also be in fluid communication with the interior of the container housing 1602, thereby completing a fluid path between a negative-pressure source and the tube 1610. The tube 1610 can be fluidly coupled to a dressing or tissue site to extend the fluid path to the dressing or tissue site.

[00104] The tube 1610 preferably has at least two lumens, and the port 1616 may also have two lumens in some embodiments. For example, in some embodiments, a first lumen of the tube 1610 may be fluidly coupled to a first lumen of the port 1616 to deliver negative-pressure to a dressing or tissue site, and a second lumen of the tube 1610 may be fluidly coupled to a second lumen of the port 1616 to provide a feedback path for negative-pressure from a dressing or tissue site. The first lumen of the port 1616 may be in fluid communication with the interior of the container housing 1602, and the second lumen of the port 1616 may be fluidly coupled to passage 1708 when assembled. In this exemplary configuration, the passage 1708 may provide a fluid path between the second lumen of the port 1616 and the channel 1702. The channel 1702 can provide a fluid path between the passage 1708 and the passage 1710, which can be in fluid communication with the port 1636. A tube or other fluid conductor, such as a tube 1902, may provide a fluid path between the port 1636 and a negative-pressure port 1904 of the instillation regulator 1604, thereby completing a fluid path between the second lumen of the tube 1610 and the negative-pressure port 1904.

[00105] Figure 20 is an assembly view illustrating another example embodiment of a fluid management system. The fluid management system 2000 of Figure 20 may include a container housing 2002 and a panel 2004. The container housing 2002 and the panel 2004 are preferably constructed from a material that is impermeable to fluid, such as a rigid or semi-rigid plastic.

[00106] The fluid management system 2000 also preferably includes an instillation regulator. For example, in some embodiments, a regulator body 2006 may be integrally molded with the panel 2004. In other embodiments, the regulator body 2006 may be inserted through an aperture in the panel 2004. In the example embodiment of Figure 20,

the regulator body 2006 has a cylindrical wall 2008 and a base 2010, and preferably has a major axis that is orthogonal to the plane of the panel 2004 to simplify molding.

[00107] Other regulator components, such as a spring 2012, a piston 2014, a first check valve 2016, a second check valve 2018, and a head 2020, may be assembled with the regulator body 2006 to provide an instillation regulator that may be analogous to the instillation regulator 1002 in many respects. For example, the piston 2014 may be disposed in the regulator body 2006 and partition the regulator body 2006 into two chambers, analogous to the first chamber 1018 and the second chamber 1020. The spring 2012 may be disposed between the piston 2014 and the base 2010, and the piston 2014 may reciprocate within the regulator body 2006. The head 2020 may be fastened to the regulator body 2006 to enclose the spring 2012 and the piston 2014. The head 2020 may also include a passage 2022 and a passage 2024. The base 2010 of the regulator body 2006 may include an aperture 2026, analogous to the negative-pressure port 1014. A hydrophobic filter 2028 is preferably disposed over the aperture 2026.

[00108] The fluid management system 2000 may also include tubes or other fluid conductors for fluidly coupling the fluid management system 2000 to a tissue site or other components of a therapy system, such as the therapy system 100. For example, as illustrated in Figure 20, the fluid management system 2000 may include a tube 2030 for coupling the fluid management system 2000 to a tissue site, a tube 2032 for coupling the fluid management system 2000 to an instillation solution source, and another tube 2034 for coupling the fluid management system 2000 to a dressing or tissue site.

[00109] Figure 21 is another assembly view illustrating additional details that may be associated with some embodiments of the fluid management system 2000. As illustrated in the example embodiment of Figure 21, the head 2020 may include a solution inlet port 2102 and a solution outlet port 2104, analogous to the solution inlet port 1010 and the solution outlet port 1012, respectively. The solution inlet port 2102 may be fluidly coupled to the passage 2022, and the solution outlet port 2104 may be fluidly coupled to the passage 2024. In some embodiments, the panel 2004 may also include additional passages, such as a passage 2106 and a passage 2108, as shown in the example embodiment of Figure 21.

[00110] The panel 2004 is preferably configured to be fastened to the container housing 2002 to form an exudate container, which may be suitable for use with some embodiments of the fluid management systems previously described. In some embodiments,

for example, the fluid management system 2000 may be assembled to provide fluid paths analogous to the fluid path 1026, the fluid path 1028, and the fluid path 1030.

[00111] For example, a fluid path analogous to the fluid path 1026 may be provided by coupling a first end of the tube 2032 to the solution inlet port 2102, and coupling a second end of the tube 2032 to an instillation solution source, such as the solution bag 1006, the syringe 1106, or the solution container 1206. The port 2102 may provide a fluid path from the tube 2032 to the passage 2022, which can be fluidly coupled to a chamber formed by the piston 2014 and the head 2020.

[00112] A fluid path analogous to the fluid path 1028 may also be assembled by coupling a first end of the tube 2034 to the solution outlet port 2104, and coupling a second end of the tube 2034 to a dressing, such as the dressing 102. The passage 2024 can provide a path between the solution outlet port 2104 and the chamber formed by the piston 2014 and the head 2020.

[00113] In some embodiments, a fluid path analogous to the fluid path 1030 may be provided by fluidly coupling the passage 2106 to a negative-pressure source, such as the negative-pressure source 104, for example. The passage 2106 may be in fluid communication with the interior of the container housing 2002, preferably through a hydrophobic filter. The aperture 2026 can also be in fluid communication with the interior of the container housing 2002. Thus, the interior of the container housing 2002 can provide a fluid path between the passage 2106 and the aperture 2026. The hydrophobic filter 2028 preferably provides a fluid path for negative-pressure between the aperture 2026 and the interior of the container housing 2002, but substantially blocks the fluid path for exudate and other liquids.

[00114] The example systems, apparatuses, and methods described herein may provide significant advantages. For example, instillation solution can be applied reliably while reducing the size, complexity, and number of parts needed for effective negative-pressure therapy with instillation. Moreover, instillation therapy can be provided even if there is a fluid head height to overcome. Some embodiments can also eliminate or reduce the need for ancillary components, such as ancillary bags for instillation solution, providing a single disposable apparatus. Some embodiments can also use a single interface pad and tubeset.

[00115] While shown in a few illustrative embodiments, a person having ordinary skill in the art will recognize that the systems, apparatuses, and methods described

herein are susceptible to various changes and modifications. Moreover, descriptions of various alternatives using terms such as “or” do not require mutual exclusivity unless clearly required by the context, and the indefinite articles "a" or "an" do not limit the subject to a single instance unless clearly required by the context.

[00116] The appended claims set forth novel and inventive aspects of the subject matter described above, but the claims may also encompass additional subject matter not specifically recited in detail. For example, certain features, elements, or aspects may be omitted from the claims if not necessary to distinguish the novel and inventive features from what is already known to a person having ordinary skill in the art. Features, elements, and aspects described herein may also be combined or replaced by alternative features serving the same, equivalent, or similar purpose without departing from the scope of the invention defined by the appended claims.

CLAIMS

What is claimed is:

1. An apparatus for managing fluid in a system for negative-pressure therapy, the apparatus comprising:
 - an exudate container;
 - a solution source; and
 - an instillation regulator coupled to the exudate container and to the solution source, the instillation regulator configured to be actuated by negative pressure from a negative-pressure source.
2. The apparatus of claim 1, wherein the instillation regulator comprises:
 - a solution inlet port fluidly coupled to the solution source;
 - a solution outlet port configured to be fluidly coupled to a dressing; and
 - a negative-pressure port configured to be fluidly coupled to the negative-pressure source.
3. The apparatus of claim 1 or claim 2, wherein the instillation regulator is disposed within an interior space of the exudate container.
4. The apparatus of claim 1 or claim 2, wherein the instillation regulator is integrally molded with the exudate container.
5. The apparatus of claim 1 or any of claims 2-4, wherein the solution source is externally mounted on the exudate container.
6. The apparatus of claim 1 or any of claims 2-4, wherein the solution source is a syringe externally mounted on the exudate container.
7. The apparatus of claim 1 or any of claims 2-4, wherein the solution source is integral with the exudate container.
8. The apparatus of claim 1 or any of claims 2-4, wherein the solution source is disposed within an interior space of the exudate container.

9. The apparatus of claim 1 or any of claims 2-4, wherein the solution source is a flexible pouch disposed within an interior space of the exudate container.

10. A system for treating a tissue site, comprising:
- a dressing configured to be placed on the tissue site;
 - an exudate container;
 - a negative-pressure source fluidly coupled to the dressing and to the exudate container, the negative-pressure source configured for a negative-pressure interval and a venting interval;
 - a solution source; and
 - an instillation regulator fluidly coupled to the solution source and to the negative-pressure source, the instillation regulator configured to draw a solution from the solution source during the negative-pressure interval and to instill the solution to the dressing during the venting interval.
11. The system of claim 10, wherein the instillation regulator comprises:
- a solution inlet port coupled to the solution source;
 - a solution outlet port coupled to the dressing; and
 - a negative-pressure port coupled to the negative-pressure source.
12. The system of claim 10, wherein the instillation regulator comprises:
- a housing coupled to the exudate container;
 - a piston disposed in the housing and partitioning the housing into a first chamber and a second chamber;
 - a solution inlet port fluidly coupled to the solution source and to the first chamber;
 - a solution outlet port fluidly coupled to the dressing and to the first chamber; and
 - a negative-pressure port fluidly coupled to the negative-pressure source and to the second chamber;
- wherein the piston is actuated by negative-pressure applied to the negative-pressure port during the negative-pressure interval to draw the solution into the first chamber through the solution inlet port and to instill the solution from the first chamber through the solution outlet port during the venting interval.
13. The system of claim 10 or any of claims 11-12, wherein the solution source is externally mounted on the exudate container.

14. The system of claim 10 or any of claims 11-12, wherein the solution source is a syringe coupled to an external surface of the exudate container.
15. The system of claim 10 or any of claims 11-12, wherein the solution source is integral with the exudate container.
16. The system of claim 10 or any of claims 11-12, wherein the solution source is disposed within the exudate container.
17. The system of claim 10 or any of claims 11-12, wherein the solution source is a flexible pouch disposed within the exudate container.
18. The system of claim 10 or any of claims 11-17, wherein the instillation regulator is disposed between the negative-pressure source and the exudate container.
19. The system of claim 10 or any of claims 11-17, wherein the instillation regulator is disposed within an interior space of the exudate container.

20. A method for treating a tissue site, the method comprising:
- applying a dressing to the tissue site;
 - coupling a negative-pressure source to the dressing, the negative-pressure source configured to provide a negative-pressure interval and a venting interval;
 - coupling an instillation regulator to the negative-pressure source and to the dressing;
 - coupling a solution source to the instillation regulator;
 - drawing a solution to the instillation regulator from the solution source during the negative-pressure interval; and
 - instilling the solution from the instillation regulator to the dressing during a venting interval.

21. The systems, apparatuses, and methods substantially as described herein.

1/25




FIG. 1





FIG. 2






FIG. 4




FIG. 5A




FIG. 5B




FIG. 6

8/25





FIG. 7A



10/25




FIG. 8

11/25




FIG. 9A

12/25




FIG. 9B




FIG. 9C

14/25




FIG. 10




FIG. 11




FIG. 12

17/25




FIG. 13




FIG. 14

19/25




FIG. 15




FIG. 16




FIG. 17

22/25




FIG. 18

23/25




FIG. 19




FIG. 20




FIG. 21

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2015/057240

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61M1/00
ADD.
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
Minimum documentation searched (classification system followed by classification symbols)
A61M
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2008/140029 A1 (SMITH JOSHUA DAVID [US] ET AL) 12 June 2008 (2008-06-12) abstract; figure 2 paragraphs [0034] - [0036], [0048], [0054]	1-5, 7-11, 13-19
X	US 5 176 642 A (CLEMENT THOMAS P [US]) 5 January 1993 (1993-01-05) column 8, lines 12-46; figure 5	1-5,7-9
Y		6
A		12
X	US 2002/068913 A1 (FLEISCHMANN WILHELM [DE]) 6 June 2002 (2002-06-06) abstract; figures 1,3 paragraphs [0030] - [0036]	10,11, 13-19 14
Y		
	-/--	

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search 11 February 2016	Date of mailing of the international search report 19/02/2016
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Kaden, Malte

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2015/057240

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 20
because they relate to subject matter not required to be searched by this Authority, namely:
Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy
2. Claims Nos.: 21
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2015/057240

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2013/211318 A1 (CROIZAT PIERRE [DE] ET AL) 15 August 2013 (2013-08-15) abstract; claim 1; figures -----	10,11, 13-19
Y	WO 01/37922 A2 (HENLEY ALAN WAYNE [US]; PETROSENKO ROBERT [US]; RISK JAMES ROBERT JR []) 31 May 2001 (2001-05-31) abstract; figures 1,3,4 -----	6,14

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/US2015/057240

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2008140029	A1	12-06-2008	NONE

US 5176642	A	05-01-1993	AU 1765392 A 06-10-1992
			US 5176642 A 05-01-1993
			WO 9215350 A1 17-09-1992

US 2002068913	A1	06-06-2002	DE 19722075 C1 01-10-1998
			US 6398767 B1 04-06-2002
			US 2002068913 A1 06-06-2002

US 2013211318	A1	15-08-2013	CN 104039286 A 10-09-2014
			EP 2626049 A1 14-08-2013
			EP 2811955 A1 17-12-2014
			HK 1198417 A1 24-04-2015
			JP 2015511150 A 16-04-2015
			US 2013211318 A1 15-08-2013
			WO 2013117318 A1 15-08-2013

WO 0137922	A2	31-05-2001	AT 400315 T 15-07-2008
			AU 780354 B2 17-03-2005
			AU 3271601 A 04-06-2001
			CA 2390131 A1 31-05-2001
			CZ 20021868 A3 13-11-2002
			EP 1233808 A2 28-08-2002
			EP 1977776 A2 08-10-2008
			ES 2307552 T3 01-12-2008
			HU 0500055 A2 28-07-2005
			JP 4681185 B2 11-05-2011
			JP 2003520072 A 02-07-2003
			KR 20030009325 A 29-01-2003
			MX PA02005277 A 22-09-2003
			NO 20022526 A 28-05-2002
			PL 366290 A1 24-01-2005
			US 2002161317 A1 31-10-2002
			US 2002183702 A1 05-12-2002
			WO 0137922 A2 31-05-2001

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.1

Claims Nos.: 20

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

Continuation of Box II.2

Claims Nos.: 21

Claim 21 contains a reference to the description. According to Rule 6.2(a) PCT, claims shall not, except where absolutely necessary rely, in respect of the technical features of the invention, on references to the description or drawings. In the present case it appears possible to define the subject-matter claimed in technical terms. Consequently, claim 21 has not been searched.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guidelines C-IV, 7.2), should the problems which led to the Article 17(2) declaration be overcome.